Literature DB >> 9893738

Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.

D J Touw1.   

Abstract

Hepatic oxidation is a major drug metabolising process and is carried out by the cytochrome P-450 monooxygenase system. This system consists of a variety of isoenzymes among which the cytochromes 1A2, 2C8, 2C9/10, 2C19, 2D6, 2E1 and 3A4 are involved in the oxidative metabolism of drugs. Interindividually, large differences in capacities are found. These differences are partly due to genetic constitution (genetic polymorphism, which has been proved to exist for CYP2D6 and CYP2C19) and partly due to environmental factors, among which the administration of interfering drugs can play a major role.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9893738

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN： 0792-5077


  13 in total

1.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.

Authors:  Rachel Puech; Marie-Claude Gagnieu; Caroline Planus; Bruno Charpiat; André Boibieux; Tristan Ferry; Michel Tod
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 3.  Pharmacogenomics: the promise of personalized medicine.

Authors:  L Mancinelli; M Cronin; W Sadée
Journal:  AAPS PharmSci       Date:  2000

4.  Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.

Authors:  K E Zhang; E Wu; A K Patick; B Kerr; M Zorbas; A Lankford; T Kobayashi; Y Maeda; B Shetty; S Webber
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.

Authors:  Barbara Gawrońska-Szklarz; Andrzej Siuda; Mateusz Kurzawski; Dariusz Bielicki; Wojciech Marlicz; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2010-04-08       Impact factor: 2.953

6.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 7.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.

Authors:  Katja Grasmäder; Petra Louise Verwohlt; Marcella Rietschel; Aleksandra Dragicevic; Matthias Müller; Christoph Hiemke; Nikolaus Freymann; Astrid Zobel; Wolfgang Maier; Marie Luise Rao
Journal:  Eur J Clin Pharmacol       Date:  2004-05-28       Impact factor: 2.953

9.  Psychiatric diseases: Need for an increased awareness among the anesthesiologists.

Authors:  Sukhminder Jit Singh Bajwa; Ravi Jindal; Jasbir Kaur; Amarjit Singh
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-10

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.